Riskpilot← Back to searchSign inGet full accessRenapharma AB
ABActiveOrg 5565718946Riddargatan 16 2trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 19994 employees
Revenue 2024
SEK 35,6M
+18% vs 2023
EBITDA margin
22.1%
+10% vs 2023
Equity ratio
74.1%
Financial strength
Net profit 2024
SEK 4,1M
-38% vs 2023
| Revenue | SEK 35,6M | +18% |
| EBITDA | SEK 7,9M | +10% |
| Net profit | SEK 4,1M | -38% |
| Total assets | SEK 41,3M | -7% |
| Equity | SEK 30,6M | +16% |
| Employees | 4 | — |
Legal name
Renapharma AB
Org number
5565718946
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 juni 1999
Share capital
SEK 100 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Widén, Urban Håkan Zetterberg, Jan Gustaf
Company purpose
Bolaget skall bedriva utveckling, forskning och försäljning av läkemedel ävensom idka därmed förenlig verksamhet.
Address
Riddargatan 16 2tr
Phone
+46187001140
Email
info@renapharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 17 715 | 15 203 | 17 225 | 23 103 | 30 159 | 30 205 | 35 635 |
| Staff expenses | — | — | — | — | — | — | — | −7 472 | −3 606 | −3 784 |
| EBITDA | 1 597 | −3 849 | −1 844 | 2 159 | 1 229 | 2 745 | 9 218 | 7 899 | 7 171 | 7 867 |
| Depreciation & amort. | −1 124 | −1 037 | −2 480 | −1 391 | −1 038 | −886 | −1 146 | −534 | −538 | −2 801 |
| EBIT | 473 | −4 886 | −4 324 | 768 | 191 | 1 859 | 8 072 | 7 365 | 6 633 | 5 066 |
| Net financials | −4 | −3 | −4 | −6 | −68 | −215 | −128 | 9 | −29 | 280 |
| Profit before tax | 470 | −4 890 | −4 327 | 613 | 123 | 1 644 | 7 962 | 7 374 | 6 603 | 4 589 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | −469 |
| Net profit | 470 | −4 890 | −4 327 | 613 | 123 | 1 644 | 7 962 | 7 374 | 6 603 | 4 120 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 16 820 | 11 584 | 9 918 | 11 648 | 16 834 | 21 408 | 25 991 | 37 136 | 44 263 | 41 324 |
| Equity | 596 | 206 | 178 | 791 | 914 | 4 559 | 12 520 | 19 894 | 26 497 | 30 617 |
| Long-term debt | 12 737 | 8 684 | 5 401 | 5 528 | 11 865 | 11 505 | 11 373 | 9 534 | 8 102 | 5 789 |
| Short-term debt | 3 487 | 2 694 | 4 339 | 5 329 | 4 055 | 5 344 | 2 098 | 7 708 | 9 664 | 4 160 |
| Total debt | 16 224 | 11 378 | 9 740 | 10 857 | 15 920 | 16 849 | 13 471 | 17 242 | 17 766 | 9 949 |
EBITDA margin
22.1%
This company
15.8%
Market median
+40% vs market
20152024
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20152024
Return on equity
13.5%
This company
18.4%
Market median
+27% vs market
20152024
Net profit margin
11.6%
This company
8.1%
Market median
+43% vs market
20152024
Asset turnover
0.86×
This company
1.12×
Market median
+23% vs market
20152024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-07-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PG Audit | Audit | 2021 | — | — |
LM Auditor Substitute | Auditor Substitute | 2021 | — | — |
UH Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Renapharma Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
RENAPHARMA AG
Renapharma AB Board members of Renapharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Gustaf Hammar | Audit | 0 companies |
| Lars Mattias Eklöf | Auditor Substitute | 0 companies |
| Urban Håkan Widén | Chief Executive Officer | 0 companies |
| Kerstin Anna-Margit Danielson | Board of Directors | 0 companies |
| Carl Fredrik Magnus Danielson | Board of Directors | 0 companies |
| Anna Kristin Danielson Pistis | Board of Directors | 0 companies |
| Anna Malin Caroline Danielson | Board of Directors | 0 companies |
| Niels Fischer | Chairman | 0 companies |
| Jan Gustaf Zetterberg | Chairman | 0 companies |